Evidence map›Paper›PMID 39291016›Full record

ArticleACS medicinal chemistry letters2024

Open Source Code Contributions to Global Health: The Case of Antimalarial Drug Discovery.

Gemma Turon, Edwin Tse, Xin Qiu, Matthew Todd, Miquel Duran-Frigola

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gemma TuronErsilia Open Source Initiative, Barcelona 08039, Spain.
Edwin TseSchool of Pharmacy, University College London, London WC1N 1AX, U.K.
Xin QiuSchool of Pharmacy, University College London, London WC1N 1AX, U.K.
Matthew ToddSchool of Pharmacy, University College London, London WC1N 1AX, U.K.ORCID https://orcid.org/0000-0001-7096-4751
Miquel Duran-FrigolaErsilia Open Source Initiative, Barcelona 08039, Spain.ORCID https://orcid.org/0000-0002-9906-6936

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of treatments for infectious diseases that affect the poorest countries has been stagnant for decades. As long as expected returns on investment remain low, pharmaceutical companies' lack of interest in this disease area must be compensated for with collaborative efforts from the public sector. New approaches to drug discovery, inspired by the "open source" philosophy prevalent in software development, offer a platform for experts from diverse backgrounds to contribute their skills, enhancing reproducibility, progress tracking, and public discussion. Here, we present the first efforts of Ersilia, an initiative focused on attracting data scientists into contributing to global health, toward meeting the goals of Open Source Malaria, a consortium of medicinal chemists investigating antimalarial compounds using a purely open science approach. We showcase the chemical space exploration of a set of triazolopyrazine compounds with potent antiplasmodial activity and discuss how open source practices can serve as a common ground to make drug discovery more inclusive and participative.

Identifiers

PMID39291016
PMCPMC11403727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.